中华肿瘤杂志
中華腫瘤雜誌
중화종류잡지
CHINESE JOURNAL OF ONCOLOGY
2013年
10期
751-753
,共3页
李清怀%张晓娟%李筱雨%底旺%张霖雷
李清懷%張曉娟%李篠雨%底旺%張霖雷
리청부%장효연%리소우%저왕%장림뢰
甲状腺肿瘤%免疫组织化学%促甲状腺激素受体%治疗
甲狀腺腫瘤%免疫組織化學%促甲狀腺激素受體%治療
갑상선종류%면역조직화학%촉갑상선격소수체%치료
Thyroid neoplasms%Immunohistochemistry%Thyroid stimulating hormone receptor%Therapy
目的 探讨促甲状腺激素(TSH)受体在分化型甲状腺癌中的表达及意义.方法 采用免疫组化染色检测74例分化型甲状腺癌患者和28例结节性甲状腺肿患者甲状腺组织中TSH受体的表达,分析其与分化型甲状腺癌患者TNM分期和淋巴结转移的关系.结果 TSH受体在结节性甲状腺肿组织中的阳性表达率为89.3%,明显高于分化型甲状腺癌组织(55.4%;x2=10.21,P<0.05).TSH受体在Ⅰ期、Ⅱ期、Ⅲ期和Ⅳ期分化型甲状腺癌组织中的阳性表达率分别为75.9%、47.8%、38.9%和25.0%,随着临床分期的升高,阳性表达率逐渐下降.统计学分析的结果显示,TSH受体的表达与分化型甲状腺癌的TNM分期相关(P<0.05),而与淋巴结转移无关(P>0.05).结论 TSH受体在分化型甲状腺癌组织中的阳性表达率较低,且随着TNM分期的增加,TSH受体的阳性表达率逐渐下降.TSH受体表达水平的检测可为分化型甲状腺癌患者术后进行TSH抑制治疗提供依据.
目的 探討促甲狀腺激素(TSH)受體在分化型甲狀腺癌中的錶達及意義.方法 採用免疫組化染色檢測74例分化型甲狀腺癌患者和28例結節性甲狀腺腫患者甲狀腺組織中TSH受體的錶達,分析其與分化型甲狀腺癌患者TNM分期和淋巴結轉移的關繫.結果 TSH受體在結節性甲狀腺腫組織中的暘性錶達率為89.3%,明顯高于分化型甲狀腺癌組織(55.4%;x2=10.21,P<0.05).TSH受體在Ⅰ期、Ⅱ期、Ⅲ期和Ⅳ期分化型甲狀腺癌組織中的暘性錶達率分彆為75.9%、47.8%、38.9%和25.0%,隨著臨床分期的升高,暘性錶達率逐漸下降.統計學分析的結果顯示,TSH受體的錶達與分化型甲狀腺癌的TNM分期相關(P<0.05),而與淋巴結轉移無關(P>0.05).結論 TSH受體在分化型甲狀腺癌組織中的暘性錶達率較低,且隨著TNM分期的增加,TSH受體的暘性錶達率逐漸下降.TSH受體錶達水平的檢測可為分化型甲狀腺癌患者術後進行TSH抑製治療提供依據.
목적 탐토촉갑상선격소(TSH)수체재분화형갑상선암중적표체급의의.방법 채용면역조화염색검측74례분화형갑상선암환자화28례결절성갑상선종환자갑상선조직중TSH수체적표체,분석기여분화형갑상선암환자TNM분기화림파결전이적관계.결과 TSH수체재결절성갑상선종조직중적양성표체솔위89.3%,명현고우분화형갑상선암조직(55.4%;x2=10.21,P<0.05).TSH수체재Ⅰ기、Ⅱ기、Ⅲ기화Ⅳ기분화형갑상선암조직중적양성표체솔분별위75.9%、47.8%、38.9%화25.0%,수착림상분기적승고,양성표체솔축점하강.통계학분석적결과현시,TSH수체적표체여분화형갑상선암적TNM분기상관(P<0.05),이여림파결전이무관(P>0.05).결론 TSH수체재분화형갑상선암조직중적양성표체솔교저,차수착TNM분기적증가,TSH수체적양성표체솔축점하강.TSH수체표체수평적검측가위분화형갑상선암환자술후진행TSH억제치료제공의거.
Objective To explore the expression of thyroid stimulating hormone (TSH) receptor in differentiated thyroid carcinoma and its clinical significance.Methods Seventy-four patients with differentiated thyroid carcinoma treated in our department from January 2009 to January 2011 were selected as the observation group,and 28 patients with nodular goiter were selected as the control group.Expression of TSH receptor in the two groups were detected by immunohistochemistry.Results The positive rate of TSH receptor expression in the observation group was 55.4 (41/74),significantly lower than that of the control group (89.3%,25/28),with a significant difference between the two groups (x2 =10.21,P <0.05).In the observation group,the positive rate of TSH receptor expression was 75.9% (22/29) in the stage Ⅰ patients,47.8% (11/23) in the stage Ⅱ patients,38.9%6 (7/18) in the stage Ⅲ patients,and 25.0% (1/4) in the stage Ⅳ patients.Along with the increase of TNM staging,the positive rate of TSH receptor expression was decreased gradually,with a significant difference between them (x2 =8.93,P <0.05).The positive rate of TSH receptor expression was 53.8% (14/26) in the lymph node metastasis positive group and 56.3% (27/48) in the lymph node metastasis negative groups,with a non-significant difference between them (x2 =0.04,P > 0.05).Conclusions Expression of TSH receptors in the patients with differentiated thyroid carcinoma is quite low,and along with the increase of TNM staging,its positive rate is decreasing gradually.Testing the expression of TSH receptor may provide a basis for TSH suppression therapy after thyroid cancer surgery.This TSH suppression therapy should be personalized in order to reduce the side effects and improve their quality of life.